AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet
AbbVie stock rose after the pharmaceutical company reported quarterly earnings that beat analysts' expectations and raised guidance early Friday.
First-quarter adjusted earnings per share (EPS) were $2.46 on sales of $13.3 billion, comfortably above analysts' call of $2.38 on sales of $12.9 billion, according to FactSet.
Shares rose 3.3% in premarket trading immediately after the results.
The company raised its full-year profit guidance and now sees adjusted EPS for 2025 of between $12.09 and $12.29, up from between $11.99 and $12.19 previously.
The guidance doesn't reflect shifts in U.S. trade policy -- including pharmaceutical sector tariffs -- that could affect its business going forward, the drugmaker said.
AbbVie stock is up 1.5% so far this year -- outperforming the benchmark S&P 500 index, which is down 6.8% over the same period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10